Therapeutic efficacy and clinical effectiveness of mycophenolate mofetil and dexamethasone for immune thrombocytopenia: A retrospective observational study

被引:0
作者
Wasekar, Nilesh [1 ]
Badarkhe, Girish [1 ]
Pandit, Sudarshan [1 ]
Ramesh, Yasam Venkata [2 ]
Nagarkar, Raj [3 ]
机构
[1] HCG Manavata Canc Ctr, Dept Hematol, Nasik 422011, Maharashtra, India
[2] HCG Manavata Canc Ctr, Dept Acad, Nasik, Maharashtra, India
[3] HCG Manavata Canc Ctr, Dept Surg Oncol, Nasik, Maharashtra, India
关键词
Autoimmune disease; dexamethasone; immune thrombocytopenia; mycophenolate mofetil; SPLENECTOMY; RITUXIMAB; PURPURA; ADULTS; MANAGEMENT; CHILDREN; SAFETY;
D O I
10.4103/ijh.ijh_50_20
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BACKGROUND: Immune thrombocytopenia (ITP) is an autoimmune hemorrhagic disorder, where autoreactive T-cells and/or autoantibodies destroy platelets and megakaryocytes in the spleen and bone marrow, respectively. To the best of our knowledge, this is the largest cohort of cases wherein patients were treated with novel combination therapy of a corticosteroid with an adjunct immunosuppressive agent for the treatment of ITP in adults. In cohort of 23 patients, 11 patients have no response and 12 patients have shown partial to complete response (CR) to the treatment. The primary aim of the present study was to explore the safety and efficacy of combination therapy in chronic ITP along by evaluating the toxicity associated with prolonged steroid exposure. The secondary aim was to compare the cost benefit with other available modalities for chronic ITP treatment. MATERIALS AND METHODS: A retrospective observational study was carried out by collecting data from electronic medical records of all the ITP patients treated at HCG Manavata Cancer Centre, India, between May 1, 2019, and April 30, 2020. Inclusion and exclusion criteria were strictly followed for data collection and analysis. RESULTS: Twelve (52%) of the 23 patients have shown response to the combinational therapy; 5 (22%) patients achieved a partial response (PR) and 7 (30%) achieved a CR. In the PR group, 3 patients developed thrombocytopenia and 1 switched to thrombopoietin receptor agonists, whereas in 7 CR patients, 6 have maintained it until end and 1 patient was switched to maintenance therapy. CONCLUSION: A combination of immunosuppressant and corticosteroid on ITP patients appeared to be effective, tolerable, with minimal adverse side effects, and an economical alternative. Therefore, this novel combination therapy may be an excellent alternative for the treatment of patients with ITP in clinical settings.
引用
收藏
页码:28 / 33
页数:6
相关论文
共 17 条
  • [1] Optimal use of thrombopoietin receptor agonists in immune thrombocytopenia
    Al-Samkari, Hanny
    Kuter, David J.
    [J]. THERAPEUTIC ADVANCES IN HEMATOLOGY, 2019, 10 : 1 - 13
  • [2] Systematic review: Efficacy and safety of rituximab for adults with idiopathic thrombocytopenic purpura
    Arnold, Donald M.
    Dentali, Francesco
    Crowther, Mark A.
    Meyer, Ralph M.
    Cook, Richard J.
    Sigouin, Christopher
    Fraser, Graeme A.
    Lim, Wendy
    Kelton, John G.
    [J]. ANNALS OF INTERNAL MEDICINE, 2007, 146 (01) : 25 - W5
  • [3] Combination immunosuppressant therapy for patients with chronic refractory immune thrombocytopenic purpura
    Arnold, Donald M.
    Nazi, Ishac
    Santos, Aurelio
    Chan, Howard
    Heddle, Nancy M.
    Warkentin, Theodore E.
    Kelton, John G.
    [J]. BLOOD, 2010, 115 (01) : 29 - 31
  • [4] Rituximab efficacy and. safety in adult splenectomy candidates with chronic immune thrombocytopenic purpura:: results of a prospective multicenter phase 2 study
    Godeau, Bertrand
    Porcher, Raphael
    Fain, Olivier
    Lefrere, Francois
    Fenaux, Pierre
    Cheze, Stephane
    Vekhoff, Anne
    Chauveheid, Marie-Paule
    Stirnemann, Jerome
    Galicier, Lionel
    Bourgeois, Emmanuelle
    Haiat, Stephanie
    Varet, Bruno
    Leporrier, Michel
    Papo, Thomas
    Khellaf, Mehdi
    Michel, Marc
    Bierling, Philippe
    [J]. BLOOD, 2008, 112 (04) : 999 - 1004
  • [5] Mycophenolate mofetil (MMF) for the treatment of steroid-resistant idiopathic thrombocytopenic purpura
    Hou, M
    Peng, J
    Shi, Y
    Zhang, CQ
    Qin, P
    Zhao, CL
    Ji, XB
    Wang, XY
    Zhang, MH
    [J]. EUROPEAN JOURNAL OF HAEMATOLOGY, 2003, 70 (06) : 353 - 357
  • [6] Mycophenolate mofetil for the treatment of refractory auto-immune haemolytic anaemia and auto-immune thrombocytopenia purpura
    Howard, J
    Hoffbrand, AV
    Prentice, HG
    Mehta, A
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2002, 117 (03) : 712 - 715
  • [7] Khan Ayesha M, 2017, P T, V42, P756
  • [8] Immune Thrombocytopenia
    Kistangari, Gaurav
    McCrae, Keith R.
    [J]. HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2013, 27 (03) : 495 - +
  • [9] Splenectomy for adult patients with idiopathic thrombocytopenic purpura: a systematic review to assess long-term platelet count responses, prediction of response, and surgical complications
    Kojouri, K
    Vesely, SK
    Terrell, DR
    George, JN
    [J]. BLOOD, 2004, 104 (09) : 2623 - 2634
  • [10] Efficacy of mycophenolate mofetil in adult refractory auto-immune cytopenias: a single center preliminary study
    Kotb, R
    Pinganaud, C
    Trichet, C
    Lambotte, O
    Dreyfus, M
    Delfraissy, JF
    Tchernia, G
    Goujard, C
    [J]. EUROPEAN JOURNAL OF HAEMATOLOGY, 2005, 75 (01) : 60 - 64